GlassScriptPhysician profile
Yara D Nazzal
NPI 1477845584
$1,309.73
in general payments reported to CMS, 2019-2025
26 companies · $629 in 2025
The $629 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.35 · 2023: $242 · 2024: $373 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $130.82 | 2023 | |
| Amgen INC. | $120.38 | 2021-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $117.46 | 2024-2025 | |
| Boston Scientific Corporation | $116.51 | 2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $107.10 | 2024 | Zeposia |
| Abbvie INC. | $106.26 | 2024-2025 | |
| Argenx US, INC. | $73.20 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $58.16 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $43.81 | 2024-2025 | Nuplazid |
| Ucb, INC. | $41.98 | 2023-2025 | Nayzilam |
| Genentech USA, INC. | $41.94 | 2025 | Ocrevus Zunovo |
| Pfizer INC. | $39.23 | 2024 | |
| Lilly USA, LLC | $38.32 | 2024-2025 | Emgality, Reyvow, Zepbound |
| Xeris Pharmaceuticals, INC. | $34.67 | 2024 | Keveyis |
| Celgene Corporation | $31.53 | 2025 | Zeposia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $25.05 | 2023 | Nourianz |
| Sumitomo Pharma America, INC. | $22.64 | 2023 | Aptiom |
| Corium, LLC | $22.08 | 2023 | Adlarity |
| Supernus Pharmaceuticals, INC. | $21.98 | 2021 | |
| Neurocrine Biosciences, INC. | $20.99 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.48 | 2021 | |
| Lundbeck LLC | $19.47 | 2023 | Vyepti |
| Baxter Healthcare | $14.61 | 2025 | Hillrom - Monarch Airway Clearance System |
| Takeda Pharmaceuticals U.S.A., INC. | $14.44 | 2025 | Aralast |
| Bausch Health US, LLC | $13.86 | 2025 | Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $13.76 | 2024 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yara Nazzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.